Can a low-dose seizure drug protect aging brains? new study aims to find out.
NCT ID NCT06919926
First seen Apr 17, 2026 · Last updated Apr 24, 2026 · Updated 2 times
Summary
This study tests whether a low-dose, slow-release drug called AGB101 can reduce overactivity in a key memory region of the brain in healthy older adults. Over 60 participants aged 50-80 will receive both the drug and a placebo in random order, each for two weeks. The main goal is to see if the drug calms brain activity measured by fMRI, which could help prevent memory decline.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University School of Medicine
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.